Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study

Salvatore Del Prete, Liliana Montella, Michele Caraglia, Luigi Maiorino, Gregorio Cennamo, Vincenzo Montesarchio, Guido Piai, Antonio Febbraro, Luciano Tarantino, Elena Capasso, Giovannella Palmieri, Rosario Guarrasi, Maddalena Bianco, Rosanna Mamone, Clementina Savastano, Agata Pisano, Bruno Vincenzi, Antonietta Sabia, Alberto D’Agostino, Vincenzo Faiola, Raffaele Addeo

Open source

DOI: 10.1007/s00280-009-1226-z
Published: 2009-12-30
Container: Cancer Chemotherapy and Pharmacology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00280-009-1226-z,
  title = {Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study},
  author = {Salvatore Del Prete and Liliana Montella and Michele Caraglia and Luigi Maiorino and Gregorio Cennamo and Vincenzo Montesarchio and Guido Piai and Antonio Febbraro and Luciano Tarantino and Elena Capasso and Giovannella Palmieri and Rosario Guarrasi and Maddalena Bianco and Rosanna Mamone and Clementina Savastano and Agata Pisano and Bruno Vincenzi and Antonietta Sabia and Alberto D’Agostino and Vincenzo Faiola and Raffaele Addeo},
  year = {2009},
  journal = {Cancer Chemotherapy and Pharmacology},
  doi = {10.1007/s00280-009-1226-z},
  url = {https://doi.org/10.1007/s00280-009-1226-z}
}

RIS

TY  - JOUR
TI  - Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study
AU  - Salvatore Del Prete
AU  - Liliana Montella
AU  - Michele Caraglia
AU  - Luigi Maiorino
AU  - Gregorio Cennamo
AU  - Vincenzo Montesarchio
AU  - Guido Piai
AU  - Antonio Febbraro
AU  - Luciano Tarantino
AU  - Elena Capasso
AU  - Giovannella Palmieri
AU  - Rosario Guarrasi
AU  - Maddalena Bianco
AU  - Rosanna Mamone
AU  - Clementina Savastano
AU  - Agata Pisano
AU  - Bruno Vincenzi
AU  - Antonietta Sabia
AU  - Alberto D’Agostino
AU  - Vincenzo Faiola
AU  - Raffaele Addeo
PY  - 2009
JO  - Cancer Chemotherapy and Pharmacology
DO  - 10.1007/s00280-009-1226-z
UR  - https://doi.org/10.1007/s00280-009-1226-z
ER  -

APA

Prete, S. D., Montella, L., Caraglia, M., Maiorino, L., Cennamo, G., Montesarchio, V., Piai, G., Febbraro, A., Tarantino, L., Capasso, E., Palmieri, G., Guarrasi, R., Bianco, M., Mamone, R., Savastano, C., Pisano, A., Vincenzi, B., Sabia, A., D’Agostino, A., Faiola, V., & Addeo, R. (2009). Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-009-1226-z

Source records

crossref · retrieved 2026-11-09T15:54:34.834Z